Sanofi SA
SAN
Company Profile
Business description
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
Contact
46, Avenue de la Great Army
Paris75017
FRAT: +33 153774000
E: investor.relations@sanofi.com
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
82,878
Sanofi SA News & Analysis
retirement
The top shares of Australia’s best performing super funds
And our equity analysts’ outlook for the stocks.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,091.80 | 28.70 | -0.31% |
| CAC 40 | 7,734.84 | 35.92 | 0.47% |
| DAX 40 | 23,807.13 | 210.15 | 0.89% |
| Dow JONES (US) | 45,514.95 | 106.34 | -0.23% |
| FTSE 100 | 9,221.44 | 13.23 | 0.14% |
| HKSE | 25,633.91 | 215.93 | 0.85% |
| NASDAQ | 21,798.70 | 91.01 | 0.42% |
| Nikkei 225 | 44,053.14 | 409.33 | 0.94% |
| NZX 50 Index | 13,266.58 | 14.56 | -0.11% |
| S&P 500 | 6,495.15 | 13.65 | 0.21% |
| S&P/ASX 200 | 8,812.20 | 28.70 | -0.32% |
| SSE Composite Index | 3,826.84 | 14.33 | 0.38% |